Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $1.1 million.

  • Vistagen Therapeutics' Share-based Compensation rose 148.15% to $1.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 million, marking a year-over-year increase of 508.52%. This contributed to the annual value of $4.3 million for FY2025, which is 9775.44% up from last year.
  • Latest data reveals that Vistagen Therapeutics reported Share-based Compensation of $1.1 million as of Q4 2025, which was up 148.15% from $1.1 million recorded in Q3 2025.
  • Vistagen Therapeutics' Share-based Compensation's 5-year high stood at $1.4 million during Q1 2022, with a 5-year trough of $490200.0 in Q1 2021.
  • Over the past 5 years, Vistagen Therapeutics' median Share-based Compensation value was $840250.0 (recorded in 2021), while the average stood at $845570.0.
  • In the last 5 years, Vistagen Therapeutics' Share-based Compensation skyrocketed by 18600.57% in 2022 and then tumbled by 5712.55% in 2023.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Share-based Compensation stood at $723800.0 in 2021, then grew by 3.11% to $746300.0 in 2022, then tumbled by 32.11% to $506700.0 in 2023, then skyrocketed by 113.14% to $1.1 million in 2024, then rose by 1.48% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q4 2025, $1.1 million for Q3 2025, and $916000.0 during Q2 2025.